Upstream Bio’s Phase 2 VALIANT study in severe asthma cut annualized asthma exacerbation rate by 56% with verekitug 100 mg every 12 weeks (p<0.0003) and by 39% with 400 mg every 24 weeks (p<0.02) versus placebo. Placebo-adjusted FEV1 gains at week 60 were 122 mL and 139 mL for the q12w and q24w regimens, respectively. FeNO was suppressed by 20.4 ppb (p<0.0003) and 26.3 ppb (p<0.0001), translating to roughly 44% mean reductions from baseline. A third arm, 100 mg every 24 weeks, achieved a statistically significant AAER effect but did not deliver consistent improvements on other endpoints. Safety was generally favorable and consistent with prior studies across 478 patients followed for up to 60 weeks. The core development is clear: Upstream plans to move verekitug into registrational trials in severe asthma and CRSwNP after regulatory interactions, with more than 90% of eligible Phase 2 completers already rolled into the long-term extension. The company is also advancing a Phase 2 COPD program that has passed 60% enrollment. Verekitug targets the TSLP receptor rather than the ligand, positioning the asset adjacent to—but mechanistically distinct from—the approved TSLP ligand blocker already on market. The Phase 2 design used approval-aligned measures, centering on AAER with supportive lung function and biomarker readouts. Strategically, the data set pushes two levers: a potentially competitive asthma efficacy profile and dosing intervals that could stretch to 12 or even 24 weeks. The trade-off is emerging in the dose narrative. The q12w 100 mg arm produced the stronger AAER reduction and consistent biomarker and lung function signals, while the q24w 400 mg arm delivered a more modest AAER effect but comparable FEV1 and FeNO changes. The low-dose q24w regimen underperformed on secondary endpoints. Dose selection for Phase 3 will signal whether Upstream prioritizes maximal exacerbation risk reduction or visit burden reduction; either way, the program will need to lock a hierarchy that can carry regulatory and payer scrutiny, especially since secondary endpoints in Phase 2 were not powered for definitive inference. For sites and CROs, the operational profile is attractive. Longer dosing intervals reduce chair time and staffing pressure, and the high rollover rate suggests manageable tolerability and patient acceptability. If a q24w arm advances, retention and interval safety monitoring become the central execution risks, favoring remote PRO capture and tighter reminder logistics. Expect FeNO and eosinophil stratification to feature more prominently in Phase 3 screening and analyses, both to satisfy regulators seeking breadth across inflammatory phenotypes and to prepare for payer negotiations that increasingly hinge on biomarker-defined value. Vendors enabling decentralized safety follow-up and adherence verification will be relevant if visit cadence falls. The next milestone is dose and endpoint clarity following FDA and ex-U.S. guidance, along with details on inclusion criteria and subgroup objectives, particularly around Type 2–low disease and any oral corticosteroid–sparing ambitions. Seasonality and event accrual planning will matter given the AAER primary, as will geographic mix to stabilize exacerbation capture. The COPD readout cadence could influence portfolio sequencing and capital allocation. Finally, the competitive bar in respiratory biologics is high; verekitug’s differentiation must be demonstrated, not inferred from mechanism or dosing convenience. Watch for full Phase 2 data at a medical meeting, Phase 3 protocol disclosures, and whether Upstream pursues a single-dose path or a dual-dose strategy to hedge efficacy versus convenience in registrational trials across asthma and CRSwNP.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
